Inetagugene geperpavec is under clinical development by Krystal Biotech and currently in Phase II for Harlequin Ichthyosis (Autosomal Recessive Congenital Ichthyosis 4B). According to GlobalData, Phase II drugs for Harlequin Ichthyosis (Autosomal Recessive Congenital Ichthyosis 4B) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Inetagugene geperpavec LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Inetagugene geperpavec overview
KB-105 is under development for the treatment of TGM-1-deficient autosomal recessive congenital ichthyosis (ARCI). The drug candidate is administered through topical route formulated as gel and acts by targeting transglutaminase 1 (TGM-1) enzyme. It is developed based on skin TARgeted delivery (STAR-D) platform. It comprises of engineered Herpes simplex virus 1 vector.
See Also:
Krystal Biotech overview
Krystal Biotech is a gene therapy company that develops and commercializes treatments for dermatological diseases. The company’s pipeline includes B-VEC (bercolagene telserpavec) gene therapy, against dystrophic epidermolysis bullosa (DEB), KB105 therapy, targeting autosomal recessive congenital ichthyosis (ARCI), a genetic skin disease caused due to deficiency of TGM1 gene. Krystal Biotech also investigating KB301, to treat aesthetic skin conditions, KB104, against Netherton Syndrome, KB407, for the treatment of Junctional Epidermolysis Bullosa (JEB) and KB5XX, targeting chronic skin diseases. The company utilizes the skin TARgeted Delivery (STAR-D) platform to develop treatments for skin diseases. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, the US.
For a complete picture of Inetagugene geperpavec’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
